The UK will launch a first-of-its-kind initiative to test how artificial intelligence (AI) can help make medicines safer for patients.
The programme will explore how AI can improve the assessment of accuracy and safety, better predict risks, and detect effects that existing approaches may not capture.
The Medicines and Healthcare products Regulatory Agency (MHRA) will establish a new regulatory “sandbox”, giving companies and researchers a controlled testing environment to work with regulators to explore how AI tools could be used to better understand medicines safety and predict potential side effects.
The programme will also explore how better use of clinical data can improve understanding of how medicines work across different groups, including those often underrepresented in studies such as children, older people and people from diverse backgrounds.
It forms part of a wider effort to modernise medicines development, including the use of advanced modelling and synthetic data to improve how safety and effectiveness are assessed.
【MORE】